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rash maculo-papular and AST increase (two each). Pharma-
cokinetics profile was similar to the preceding US phase 1 
study. Soluble HER3 concentration in serum unexpectedly 
increased in all patients. These changes did not correlate 
with clinical response. Four patients had a best response 
of stable disease. All patients tested had negative for anti-
patritumab antibody formation.
Conclusions Patritumab was well tolerated up to 18 mg/
kg without DLTs in Japanese patients with advanced solid 
tumors. Soluble HER3 increased in all patients.
Keywords U3-1287 · Patritumab · HER3 · Phase 1 
study · Solid tumor
Introduction
The human epidermal growth factor receptor-3 (HER3) is 
expressed in many normal tissues and in a variety of solid 
tumors [1, 2]. Unlike other HER family members, HER3 
lacks intrinsic kinase activity [3]. However, the cytoplasmic 
tail of HER3 contains six docking sites for the p85 regu-
latory subunit of phosphatidylinositol-3-kinase (PI3K) and 
serves as a scaffold for PI3K/protein kinase B signaling for 
the HER family via heterodimeric interactions with other 
HER family members [4–6]. Increased levels of HER3 
have been associated with a negative clinical prognosis, 
including survival in several tumor types [7–11]. Recent 
data suggest that HER3 is involved in resistance to other 
HER receptor-targeted therapeutics, e.g., trastuzumab, 
lapatinib, cetuximab, gefitinib and erlotinib [12–16].
Patritumab (U3-1287) is a fully human monoclonal 
immunoglobulin G1 (IgG1) antibody directed against 
HER3. Patritumab inhibits ligand binding (heregulin alpha 
and heregulin beta) and receptor activation and induces 
Abstract 
Purpose Patritumab (U3-1287) is a human epidermal 
growth factor receptor-3 (HER3)-targeted antibody that 
blocks ligand-associated activation of HER3. This open-
label, phase 1 and dose-finding study (ClinicalTrials.jp 
Identifier: JapicCTI-101262) aimed to assess the safety, 
pharmacokinetics, incidence of anti-patritumab antibody, 
recommended dose for subsequent clinical studies, prelimi-
nary efficacy, and patritumab-related biomarkers in Japa-
nese patients with advanced solid tumors.
Methods Patients received patritumab 9 or 18 mg/kg 
intravenously every 3 weeks until disease progression or 
intolerable toxicity occurred. Adverse events (AEs) were 
assessed according to the National Cancer Institute Com-
mon Terminology Criteria for Adverse Events (CTCAE 
version 4.0). Dose-limiting toxicities (DLTs) were evalu-
ated from the initial dose to Cycle 1 Day 21. Tumor 
response was assessed with Response Evaluation Criteria 
in Solid Tumors (RECIST version 1.1).
Results Nine patients received patritumab 9 mg/kg 
(n = 3) or 18 mg/kg (n = 6). Five patients were male, all 
patients had Eastern Cooperative Oncology Group per-
formance status (PS) ≤ 1, and median (range) age of 67 
(50–69) years. No DLTs were reported. Patritumab-related 
AEs reported in ≥2 patients were ALT increase (three 
patients), thrombocytopenia, diarrhea, stomatitis, cheilitis, 
H. Wakui · N. Yamamoto · S. Nakamichi · Y. Tamura · 
H. Nokihara · T. Tamura (*) 
Department of Thoracic Oncology, National Cancer Center 
Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
e-mail: ttamura@ncc.go.jp
Y. Yamada 
Department of Gastrointestinal Oncology, National Cancer 
Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
512 Cancer Chemother Pharmacol (2014) 73:511–516
1 3
HER3 down-regulation. Functionally, patritumab inhibits 
tumor cell proliferation, survival and anchorage-independ-
ent growth in vitro, and inhibits growth of HER3 express-
ing xenograft tumor models in vivo [17–20].
In a preceding US Phase 1 study (ClinicalTrials.gov 
Identifier: NCT00730470) [21], the tolerability of patri-
tumab was evaluated up to the dose of 20 mg/kg with-
out dose-limiting toxicities (DLTs). The most frequently 
reported patritumab-related adverse events (AEs) were 
fatigue (12/57, 21.1 %), diarrhea (7/57, 12.3 %) and nau-
sea (6/57, 10.5 %). The majority of patritumab-related AEs 
were Grade 1 or 2. This was an open-label, phase 1 and 
dose-finding study to evaluate the safety, pharmacokinet-
ics (PK) of repeated administration of patritumab and pre-




Eligible patients had histologically or cytologically con-
firmed advanced solid tumors that were refractory to 
standard treatment and were well known to express HER3 
(e.g., lung, breast, colorectal, cervical, esophageal and sar-
coma). Eligibility criteria also included the following: age 
20–75 years at informed consent; Eastern Cooperative 
Oncology Group (ECOG) performance status (PS) 0–1; 
life expectancy greater than 3 months; no previous chem-
otherapy, radiation therapy, hormonal therapy or surgery 
within 4 weeks before treatment with patritumab (6 weeks 
for previous treatment with nitrosoureas or mitomycin 
C); and adequate hematologic, hepatic and renal function. 
Any toxicity related to prior therapy must have recovered. 
Exclusion criteria included: previous treatment with other 
anti-HER3-targeted therapy; symptomatic brain metasta-
sis; pleural effusion and ascites that required drainage; a 
history of thromboembolic disease or bleeding diatheses; 
serious preexisting medical conditions such as uncon-
trolled infections, severe cardiovascular or cerebrovascu-
lar disease, uncontrolled hypertension or diabetes melli-
tus, chronic diarrhea, inflammatory bowel disease, partial 
ileus and psychiatric disorders; a history of hypersensitivity 
reactions to any drugs; a history of serious hypersensitiv-
ity to drug containing polysorbate 20; hepatic B or C virus 
or human immunodeficiency virus infection; pregnancy or 
lactation; and not willing to use contraception during and 
after 6 months of the study.
Written informed consent was obtained from all 
patients. This study was conducted in accordance with the 
Declaration of Helsinki and the applicable guidelines on 
good clinical practice, and the protocol and the informed 
consent received institutional review board/independent 
ethics committee approval.
Study design
This was an open-label, phase 1 and dose-finding study con-
ducted at National Cancer Center Hospital, Tokyo, Japan. 
The primary objective was to evaluate the safety and PK of 
patritumab in Japanese patients with advanced solid tumors. 
Secondary objectives were to determine recommended dose 
for subsequent clinical studies, to evaluate incidence of anti-
patritumab antibody, to preliminary assess tumor response 
and to explore patritumab-related biomarkers.
Drug administration and dose-escalation procedure
Eligible patients received intravenous administration of 
patritumab at a dose of 9 or 18 mg/kg every 3 weeks until 
disease progression or intolerable toxicity occurred.
DLTs were evaluated from the initial dose to Cycle 1 
Day 21. DLTs were defined as any of the following tox-
icities assessed to have a causal relationship with the 
study drug: febrile neutropenia (≥38.5 °C, neutrophil 
count <1,000/μL) or Grade 4 neutropenia persisting for 
more than 7 days; Grade 4 thrombocytopenia or Grade 3 
thrombocytopenia requiring blood transfusion; uncontrolla-
ble Grade 3 or worse fatigue, anorexia, nausea, vomiting or 
diarrhea despite maximal supportive treatment; and Grade 
3 or worse toxicities except for above three definitions. 
However, fever without neutropenia and transient electro-
lyte abnormality did not qualify as DLTs.
Dose levels were escalated from 9 mg/kg according to 
the typical 3 + 3 design.
Safety assessments
AEs were evaluated according to the National Cancer Insti-
tute Common Terminology Criteria for Adverse Events 
(CTCAE version 4.0) throughout the treatment period until 
30 days after the last dose. Safety evaluations were based 
upon medical review of AEs and the results of clinical lab-
oratory tests, vital sign measurements, 12-lead electrocardi-
ograms, physical examination, ECOG PS, X-ray/computed 
tomography scan. Anti-patritumab antibody was assessed 
before each treatment cycle. Anti-patritumab antibody was 
measured by Electrochemiluminescence Immunoassay.
Pharmacokinetic analyses
Blood samples for PK evaluation were collected on pre-
dose and 0.25, 4, 7, 24 and 72 h after the first dose, on 
Day 8 and 15 of Cycle 1, Day 1 of Cycle 2, 3, and 4 and 
Day 30 of last Cycle. The U3-1287 level was measured by 
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enzyme-linked immunosorbent assay (ELISA). PK param-
eters [AUC0–21 days, Cmax, CL, Vss, and terminal half-life] 
were derived from serum patritumab concentration versus 
time. The PK parameters for the first dose were calculated 
by a non-compartmental analysis using the computer soft-
ware WinNonlin (Ver5.2, Pharsight Corp., CA, USA). PK 
statistical analyses were performed by SAS System Release 
9.1.3 (SAS Institute Japan Ltd., Tokyo, Japan).
Tumor response
Tumor response was determined for all patients with meas-
urable and/or non-measurable lesions according to Response 
Evaluation Criteria in Solid Tumors (RECIST version 1.1). 
Tumor measurements by CT or MRI were obtained at base-
line, every 6 weeks thereafter and Cycle 1 Day 21.
Serum HER3
Blood was collected on Day 1 (before administration), 2, 8 
and 15 of Cycle 1, Day 1 (before administration) of even-
numbered cycles, and during the follow-up period to evalu-
ate the change in the serum soluble HER3 level. The solu-
ble HER3 level was measured by ELISA.
Biomarkers using tumor tissue
Biomarker research using the tumor tissue was performed 
for only patients who had written informed consent to par-
ticipate in biomarker research aside from the study. Par-
affin-embedded samples of tumor tissue archived before 
enrollment (whenever it was collected) were used to evalu-
ate the items below at Mosaic Laboratories. 
•	 HER3 protein expression level (by IHC method)
•	 Frequency of HER3 gene amplification (by FISH method)
Statistical method
All patients who received study medication were included 
in the analysis of safety and efficacy. Safety and efficacy 
statistical analyses were performed by SAS System Release 
8.2 (SAS Institute Japan Ltd., Tokyo, Japan).
Results
Patient characteristics
Nine patients were enrolled and treated in this study; 
three and six patients received patritumab 9 and 18 mg/
kg administration, respectively. Patient characteristics are 
listed in Table 1. There were 5 males with a median age of 
67 (range 50–69) years. Tumor types included 2 non-small-
cell lung cancer (NSCLC), 2 esophageal cancer, 2 colorec-
tal cancer, 1 breast cancer, 1 cervical cancer and 1 sarcoma. 
All patients had received previous treatment for their can-
cer. The median number of prior chemotherapy regimens 
(range) was 4 (2–7). 
Safety and tolerability
No DLTs were reported in this study. The patritumab-
related AEs reported in ≥2 patients were ALT increased 
(n = 3), thrombocytopenia (n = 2), diarrhea (n = 2), sto-
matitis (n = 2), cheilitis (n = 2), rash maculo-papular 
(n = 2) and AST increased (n = 2) (Table 2). 
The majority of patritumab-related AEs were Grade 1 
or 2 with the exception of Grade 3 lymphopenia on Cycle1 
and Grade 3 interstitial lung disease (ILD) and bacterial 
pneumonia on Cycle 3 observed in 1 patient. No Grade 4 
or 5 AEs were reported throughout the study. Grade 3 lym-
phopenia occurred during the DLT evaluation period and 
was assessed as related to the study drug but resolved with-
out intervention, and no significant changes in neutrophil 
count were observed. One patient in 18 mg/kg experienced 
three serious adverse events (SAEs): ILD, bacterial pneu-
monia and ascites. Two of them (ILD and bacterial pneu-
monia) assessed as related to the study drug were recov-
ered. No AEs leading to treatment discontinuation or death 
were reported in this study. No notable changes were found 
in vital signs, 12-lead ECG, body weight or ECOG PS. All 
patients tested had negative for anti-patritumab antibody.
Table 1  Patient characteristics
9 mg/kg (%) 18 mg/kg (%) Total (%)
All enrolled 3 6 9
Gender
 Male 2 3 5
 Female 1 3 4
ECOG PS
 0 1 (33.3) 2 (33.3) 3 (33.3)
 1 2 (66.7) 4 (66.7) 6 (66.7)
Age (year)
 Median (range) 63 (50–69) 67.5 (51–69) 67 (50–69)
Primary tumor type
 NSCLC 2 (66.7) 0 2 (22.2)
 Esophageal cancer 1 (33.3) 1 (16.7) 2 (22.2)
 Colorectal cancer 0 2 (33.3) 2 (22.2)
 Breast cancer 0 1 (16.7) 1 (11.1)
 Cervical cancer 0 1 (16.7) 1 (11.1)
 Sarcoma 0 1 (16.7) 1 (11.1)
Prior chemotherapy regimens
 Median (range) 3 (2–4) 5 (2–7) 4 (2–7)
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Pharmacokinetics
The PK parameters of patritumab are summarized in Table 3. 
Plasma disappearance was biphasic and terminal half-life at 
the dose of 9 and 18 mg/kg was 10.2 and 8.98 days, respec-
tively. No accumulation due to repeated administration was 
observed (Fig. 1). PK profile of patritumab in this study was 
similar to that in the US phase 1 study (Fig. 2). 
Tumor response
Among the 9 patients evaluated in this study, 4 patients 
had stable disease (SD): NSCLC (1), colorectal cancer (1), 
breast cancer (1) and sarcoma (1); 3 patients had progres-
sive disease (PD); and 2 were not evaluated. Duration of 
SD was approximately 16 weeks for NSCLC and colorec-
tal cancer patients, and approximately 10 weeks for breast 
cancer and sarcoma patients.
Soluble HER3
Soluble HER3 (sHER3) concentration in serum increased 
in all patients after administration of patritumab (Fig. 3). 
Mean sHER3 concentration on Cycle 1 Day 1 (baseline) 
and Cycle 2 Day 1 was 4,086.00 pg/mL and 22,988.50 pg/
mL at 9 mg/kg, and 3,646.08 and 21,774.50 pg/mL at 
18 mg/kg, respectively. These changes did not correlate 
with clinical response in 9 patients. 
Biomarkers using tumor tissue
Tumor tissues for biomarker research were provided by two 
patients. One was esophageal cancer and the other was colo-
rectal cancer, both received patritumab 18 mg/kg, whose 
best response was PD and NE, respectively. For esophageal 
cancer patient, no HER3 was observed on cell membrane, 
ratio of HER3/CEN12 was 1.03 and average signal copy 
number of HER3 was 3.30. For colorectal cancer patient, 
cell membrane HER3 level was 90 % of class 0, 5 % of 
class 1+ and 5 % of class 2+, ratio of HER3/CEN12 was 
1.22 and average signal HER3 was 3.90.
Discussion
This phase 1 and dose-finding study was conducted pri-
marily to evaluate the safety after repeated administration 
of patritumab in Japanese patients. The safety, PK, anti-
patritumab antibody, recommended dose for subsequent 
clinical studies, tumor response of patritumab, sHER3 and 
biomarkers were explored in this study.
The target Ctrough was 15 μg/mL which was expected to 
sufficiently inhibit HER3 activation in humans based on the 
results of nonclinical PK/PD analyses. Only initial Ctrough 
before administration in Cycle 2 was lower than 15 μg/
mL at the dose of 9 mg/kg every 3 weeks, and all Ctrough in 
every Cycles were higher than the twice of the target Ctrough 
at the dose of 18 mg/kg every 3 weeks by PK/PD simu-
lation of the US phase 1 study [21]. Therefore, we deter-
mined two dose levels (9 and 18 mg/kg) in this study.
As to safety, no DLTs were reported at any dose level, 
and the tested doses did not reach the MTD. In the preced-
ing US phase 1 study, patritumab-related AEs were reported 
Table 2  Number of patients with major treatment-related AEs in all cycles
9 mg/kg (N = 3) 18 mg/kg (N = 6) Total (N = 9)
Grade 1 Grade 2 Grade 3 Any grades (%) Grade 1 Grade 2 Grade 3 Any grades (%) Any grades (%)
Gastrointestinal disorders
Cheilitis 1 0 0 1 (33.3) 1 0 0 1 (16.7) 2 (22.2)
Diarrhea 0 0 0 0 2 0 0 2 (33.3) 2 (22.2)
Stomatitis 0 0 0 0 2 0 0 2 (33.3) 2 (22.2)
Skin and subcutaneous tissue disorders
Rash maculo-papular 1 1 0 2 (66.7) 0 0 0 0 2 (22.2)
Blood examination
ALT increased 2 0 0 2 (66.7) 0 1 0 1 (16.7) 3 (33.3)
AST increased 1 0 0 1 (33.3) 1 0 0 1 (16.7) 2 (22.2)
Thrombocytopenia 0 0 0 0 2 0 0 2 (33.3) 2 (22.2)
Table 3  Pharmacokinetic parameters of patritumab
Pharmacokinetic parameters 9 mg/kg (N = 3) 18 mg/kg (N = 6)
mean ± SD mean ± SD
AUC0–21day (μg day/mL) 1,480 ± 181 2,300 ± 505
Cmax (μg/mL) 255 ± 39 392 ± 80
CL (mL/day/kg) 4.78 ± 0.54 6.85 ± 1.65
Vss (mL/kg) 61.6 ± 10.0 71.9 ± 23.8
t1/2 (day) 10.2 ± 0.4 8.98 ± 1.62
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Fig. 1  Plasma concentration–
time profiles of patritumab from 
baseline to 3 week of exposure
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Fig. 2  Pharmacokinetics 
parameters in Phase 1 studies in 
Japan and US
9 mg/kg
A Esophageal cancer (NE)
  B Lung cancer (SD)
  C Lung cancer (PD)
18 mg/kg
  D Sarcoma (SD)
  E Cervical cancer (PD)
  F Esophageal cancer (PD)
  G Colorectal cancer (SD)
  H Breast cancer (SD)
  I Colorectal cancer (NE)
Day 1 (Baseline) Day 2 Day 8 Day 15 Day 1 Day 1 Follow-up















































































































Fig. 3  Soluble HER3 concentration in serum, A–I represent individual patients followed by tumor types and best response inside parenthesis
516 Cancer Chemother Pharmacol (2014) 73:511–516
1 3
in 26 patients (45.6 %) including fatigue (21.1 %), diarrhea 
(12.3 %), nausea (10.5 %), decreased appetite (7.0 %) and 
dysgeusia (5.3 %). Like US phase 1 study, toxicities in this 
study were mild to moderate and were manageable. No 
infusion reaction during or after patritumab administration 
was reported in this study as reported in the US phase 1 
study. One patient in 18 mg/kg developed bacterial pneu-
monia and interstitial pneumonia with consolidation and 
bilateral ground-glass opacity by CT scans on Cycle 3. The 
patient received antibiotics and steroid therapy, and imme-
diately recovered. It was unclear that interstitial pneumonia 
was induced by patritumab.
The mean serum patritumab concentration increased 
as patritumab dose increased. The mean serum patritumab 
concentration before administration in Cycle 2 was 28.5 μg/
mL at level 1 (9 mg/kg) and 34.2 μg/mL at level 2 (18 mg/
kg), which were both higher than the target Ctrough of 15 μg/
mL. There seems to be similarity between PK profiles of 
patritumab in this study and in the US phase 1 study.
sHER3 increased over time after patritumab adminis-
tration in all patients. Several reports described that serum 
soluble HER2 (sHER2) level increases with tumor progres-
sion [22, 23]; however, the level of serum sHER3 increased 
in all patients independently from best responses. The 
mechanism of sHER3 increment remains unclear; there-
fore, further investigation is warranted.
In summary, Patritumab was well tolerated up to 18 mg/
kg without DLTs in Japanese patients with advanced solid 
tumors. PK profiles in Japanese patients were similar to the 
US phase 1 study. Soluble HER3 increased in all patients 
after patritumab administration.
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